{"title":"Treatment Pattern of Antidiabetic Drugs Use One Type II Diabetes Mellitus Patients at RSAU dr. M. Salamun","authors":"Dhiyah Malihah, Rida Emelia","doi":"10.31935/delima.v9i1.161","DOIUrl":null,"url":null,"abstract":"Diabetes mellitus is a group of metabolic diseases with characteristic of hyperglycemia that occur due to abnormalities of insulin secretion, insulin activity or both, Indonesia now ranks sixth with the highest number of diabetes after the United States, China, India, Brazil and Mexico. Based on data from the IDF Atlas in 2017, the number of diabetes in Indonesia reached 10.3 million, if not handled properly, according to the WHO the incidence of diabetes is predicted to rise to 21.3 million by 2040. This research is non-experiential observational studies were conducted using retrospective research designs to know the description of drugs use pattern and treatment pattern of antidiabetic drug use on Type II Diabetes Mellitus patiens at RSAU dr. M. Salamun in 2021. The samples were 80 medical records of patients with Type II diabetes mellitus taken in total sampling. Data presented in the form of diagram/tables and percentages. The results of this study were able to find out that the classes of oral antidiabetic durgs administered to patients were sulfonylurea 97 drugs (61.78%), biquanide 38 drugs (24.20%), alpha-glucosidase 12 drugs (7.64%), and thiazolidinedione 10 drugs (6.36%). Accuracy assessment based on the patient oral antidiabetic drug delivery are as follows: 44 patients (55%) of appropriate-drugs-doses, 69 patients (89,25%) for appropriate drug indications. \n \nKeywords: Type II Diabetes Mellitus, Treatment Pattern, RSAU dr. M. Salamun. \n ","PeriodicalId":260038,"journal":{"name":"Jurnal Delima Harapan","volume":"47 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jurnal Delima Harapan","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31935/delima.v9i1.161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Diabetes mellitus is a group of metabolic diseases with characteristic of hyperglycemia that occur due to abnormalities of insulin secretion, insulin activity or both, Indonesia now ranks sixth with the highest number of diabetes after the United States, China, India, Brazil and Mexico. Based on data from the IDF Atlas in 2017, the number of diabetes in Indonesia reached 10.3 million, if not handled properly, according to the WHO the incidence of diabetes is predicted to rise to 21.3 million by 2040. This research is non-experiential observational studies were conducted using retrospective research designs to know the description of drugs use pattern and treatment pattern of antidiabetic drug use on Type II Diabetes Mellitus patiens at RSAU dr. M. Salamun in 2021. The samples were 80 medical records of patients with Type II diabetes mellitus taken in total sampling. Data presented in the form of diagram/tables and percentages. The results of this study were able to find out that the classes of oral antidiabetic durgs administered to patients were sulfonylurea 97 drugs (61.78%), biquanide 38 drugs (24.20%), alpha-glucosidase 12 drugs (7.64%), and thiazolidinedione 10 drugs (6.36%). Accuracy assessment based on the patient oral antidiabetic drug delivery are as follows: 44 patients (55%) of appropriate-drugs-doses, 69 patients (89,25%) for appropriate drug indications.
Keywords: Type II Diabetes Mellitus, Treatment Pattern, RSAU dr. M. Salamun.
糖尿病是由于胰岛素分泌异常、胰岛素活性异常或两者兼而有之而发生的以高血糖为特征的一组代谢性疾病,印度尼西亚目前是继美国、中国、印度、巴西和墨西哥之后的第六大糖尿病患者国家。根据2017年IDF地图集的数据,印度尼西亚的糖尿病人数达到1030万,如果处理不当,据世卫组织称,到2040年,糖尿病发病率预计将上升到2130万。本研究为非经验性观察性研究,采用回顾性研究设计,了解2021年在RSAU dr. M. Salamun对2型糖尿病患者的用药模式和降糖药使用治疗模式的描述。样本为总采样的80例2型糖尿病患者病历。数据以图表/表格和百分比的形式呈现。结果发现,患者口服降糖药物的种类为磺脲类97种(占61.78%)、双胍类38种(占24.20%)、α -葡萄糖苷酶12种(占7.64%)、噻唑烷二酮类10种(占6.36%)。基于患者口服降糖药给药的准确性评估如下:44例(55%)患者使用了合适的药物剂量,69例(89,25%)患者使用了合适的药物适应症。关键词:2型糖尿病,治疗模式,RSAU。